Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMHM7JS)

Drug Name
Pasireotide Drug Info
Synonyms
Signifor; UNII-I4P76SY3N4; Pasireotide diaspartate; I4P76SY3N4; SOM230; 820232-50-6; pasireotide aspartate; Pasireotide diaspartate [EMA EPAR]; CHEBI:72313; Cyclo((2R)-2-phenylglycyl-d-tryptophyl-l-lysyl-o-(phenylmethyl)-l-tyrosyl-l-phenylalanyl-(4R)-4-((((2-aminoethyl)amino)carbonyl)oxy)-l-prolyl), l-aspartate; Signifor (TN); SOM 230; SOM-230
Indication
Disease Entry ICD 11 Status REF
Cushing disease 5A70 Approved [1]
Cross-matching ID
PubChem CID
9941444
ChEBI ID
CHEBI:72312
CAS Number
CAS 396091-73-9
TTD Drug ID
DMHM7JS

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Approved Drug(s)
Patented Agent(s)
Download the Complete Related Drug List
Drug(s) Targeting Somatostatin receptor type 3 (SSTR3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
ODT-8 DMBWO5T N. A. N. A. Phase 3 [7]
FR-121196 DMNRUGA Alzheimer disease 8A20 Terminated [8]
SOMATOSTATIN DMIOFQE Acromegaly 5A60.0 Investigative [9]
Des-AA1,2,5-[D-Trp8,Tyr11]SRIF DM7MZ2V Discovery agent N.A. Investigative [10]
Des-AA1,2,5,12,13-[D-Trp8]SRIF DM1KJAE Discovery agent N.A. Investigative [7]
SRIF-28 DM0OM9L Discovery agent N.A. Investigative [11]
99mTc-MIP-1407 DMYPD5L Neuroendocrine cancer 2B72.1 Investigative [8]
Des-AA1,2,4,12,13-[D-Trp8]SRIF DMMWDC5 Discovery agent N.A. Investigative [7]
Cytotoxin Peptide Conjugate DM7SVLZ Discovery agent N.A. Investigative [12]
Des-AA1,2,4,13-[D-Trp8]SRIF DMR6Z2N Discovery agent N.A. Investigative [7]
Triclosan DMZUR4N Malaria 1F40-1F45 Approved [36]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [28]
bisphenol A DM2ZLD7 Discovery agent N.A. Investigative [37]
⏷ Show the Full List of 13 Drug(s)
Drug(s) Targeting Somatostatin receptor type 1 (SSTR1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Lutetium Lu 177 dotatate DMN1XVC Neuroendocrine cancer 2B72.1 Approved [13]
ODT-8 DMBWO5T N. A. N. A. Phase 3 [7]
FR-121196 DMNRUGA Alzheimer disease 8A20 Terminated [8]
SOMATOSTATIN DMIOFQE Acromegaly 5A60.0 Investigative [9]
Des-AA1,2,5-[D-Trp8,Tyr11]SRIF DM7MZ2V Discovery agent N.A. Investigative [10]
Des-AA1,2,5,12,13-[D-Trp8]SRIF DM1KJAE Discovery agent N.A. Investigative [7]
SRIF-28 DM0OM9L Discovery agent N.A. Investigative [11]
99mTc-MIP-1407 DMYPD5L Neuroendocrine cancer 2B72.1 Investigative [8]
Des-AA1,2,4,12,13-[D-Trp8]SRIF DMMWDC5 Discovery agent N.A. Investigative [7]
Cytotoxin Peptide Conjugate DM7SVLZ Discovery agent N.A. Investigative [12]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [29]
Ethanol DMDRQZU Chronic pain MG30 Approved [30]
Zoledronate DMIXC7G Adenocarcinoma 2D40 Approved [31]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [32]
AZD-4877 DMFVL5J Acute myeloid leukaemia 2A60 Phase 2 [33]
(+)-JQ1 DM1CZSJ Testicular cancer 2C80 Phase 1 [34]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [28]
Trichostatin A DM9C8NX Solid tumour/cancer 2A00-2F9Z Investigative [35]
⏷ Show the Full List of 18 Drug(s)
Drug(s) Targeting Somatostatin receptor type 2 (SSTR2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Octreotide DMHIDCJ Acromegaly 5A60.0 Approved [14]
Lanreotide acetate DMG6ZU4 Acromegaly 5A60.0 Approved [15]
Ga-68-DOTATOC DMZ0P95 Diagnostic imaging N.A. Approved [16]
Copper dotatate Cu-64 DM26KR1 Diagnostic imaging N.A. Approved [17]
ODT-8 DMBWO5T N. A. N. A. Phase 3 [7]
Paltusotine DM97IN2 Acromegaly 5A60.0 Phase 3 [18]
TBR-760 DMM5BVG Pituitary adenoma 2F37.0 Phase 2 [19]
Re-188-P-2045 DM614BA Lung cancer 2C25.0 Phase 1/2 [20]
PEN-221 DMMAUOK Neuroendocrine cancer 2B72.1 Phase 1/2 [21]
FR-121196 DMNRUGA Alzheimer disease 8A20 Terminated [22]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [38]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [39]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [40]
Malathion DMXZ84M Pediculus capitis infestation 1G00.0 Approved [41]
Permethrin DMZ0Q1G Pediculus capitis infestation 1G00.0 Approved [41]
SNDX-275 DMH7W9X Breast cancer 2C60-2C65 Phase 3 [42]
Edotreotide DMQ08AJ Acromegaly 5A60.0 Phase 2 [43]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [28]
PMID26394986-Compound-22 DM43Z1G N. A. N. A. Patented [44]
Formaldehyde DM7Q6M0 Discovery agent N.A. Investigative [45]
⏷ Show the Full List of 20 Drug(s)
Drug(s) Targeting Somatostatin receptor type 5 (SSTR5)
Drug Name Drug ID Indication ICD 11 Highest Status REF
ODT-8 DMBWO5T N. A. N. A. Phase 3 [7]
FR-121196 DMNRUGA Alzheimer disease 8A20 Terminated [22]
SOMATOSTATIN DMIOFQE Acromegaly 5A60.0 Investigative [9]
Des-AA1,2,5-[D-Trp8,Tyr11]SRIF DM7MZ2V Discovery agent N.A. Investigative [10]
Des-AA1,2,5,12,13-[D-Trp8]SRIF DM1KJAE Discovery agent N.A. Investigative [7]
SRIF-28 DM0OM9L Discovery agent N.A. Investigative [11]
99mTc-MIP-1407 DMYPD5L Neuroendocrine cancer 2B72.1 Investigative [5]
Des-AA1,2,4,12,13-[D-Trp8]SRIF DMMWDC5 Discovery agent N.A. Investigative [7]
Cytotoxin Peptide Conjugate DM7SVLZ Discovery agent N.A. Investigative [12]
Des-AA1,2,4,13-[D-Trp8]SRIF DMR6Z2N Discovery agent N.A. Investigative [7]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [23]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [24]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [25]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [26]
Urethane DM7NSI0 N. A. N. A. Phase 4 [27]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [28]
⏷ Show the Full List of 16 Drug(s)
Drug(s) Affected By Somatostatin receptor type 4 (SSTR4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [24]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [28]
bisphenol A DM2ZLD7 Discovery agent N.A. Investigative [37]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Somatostatin receptor type 1 (SSTR1) TTIND6G SSR1_HUMAN Inhibitor [2]
Somatostatin receptor type 2 (SSTR2) TTZ6T9E SSR2_HUMAN Inhibitor [3]
Somatostatin receptor type 3 (SSTR3) TTJX3UE SSR3_HUMAN Inhibitor [4]
Somatostatin receptor type 5 (SSTR5) TT2BC4G SSR5_HUMAN Inhibitor [5]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Somatostatin receptor type 1 (SSTR1) OTFAGWO7 SSR1_HUMAN Protein Interaction/Cellular Processes [6]
Somatostatin receptor type 2 (SSTR2) OTFN8JM1 SSR2_HUMAN Protein Interaction/Cellular Processes [6]
Somatostatin receptor type 3 (SSTR3) OT0B1T93 SSR3_HUMAN Protein Interaction/Cellular Processes [6]
Somatostatin receptor type 4 (SSTR4) OT2KZCK7 SSR4_HUMAN Protein Interaction/Cellular Processes [6]
Somatostatin receptor type 5 (SSTR5) OTWVLRTM SSR5_HUMAN Protein Interaction/Cellular Processes [6]

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 355).
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 356).
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 357).
5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 359).
6 Medicinal chemistry of somatostatin analogs leading to the DTPA and DOTA conjugates of the multi-receptor-ligand SOM230. J Endocrinol Invest. 2005;28(11 Suppl International):15-20.
7 Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22.
8 Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
9 Discovery of iodinated somatostatin analogues selective for hsst2 and hsst5 with excellent inhibition of growth hormone and prolactin release from ... J Med Chem. 2005 Oct 20;48(21):6643-52.
10 Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14.
11 Novel octreotide dicarba-analogues with high affinity and different selectivity for somatostatin receptors. J Med Chem. 2010 Aug 26;53(16):6188-97.
12 An adjustable release rate linking strategy for cytotoxin-peptide conjugates. Bioorg Med Chem Lett. 2003 Mar 10;13(5):799-803.
13 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
14 Versatile conjugation of octreotide to dendrimers by cycloaddition ("click") chemistry to yield high-affinity multivalent cyclic Peptide dendrimers. Bioconjug Chem. 2009 Jul;20(7):1323-31.
15 Treatment strategies for acromegaly. Expert Opin Emerg Drugs. 2005 Nov;10(4):875-90.
16 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
17 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
18 Paltusotine, a novel oral once-daily nonpeptide SST2 receptor agonist, suppresses GH and IGF-1 in healthy volunteers. Pituitary. 2022 Apr;25(2):328-339.
19 TBR-760, a Dopamine-Somatostatin Compound, Arrests Growth of Aggressive Nonfunctioning Pituitary Adenomas in Mice. Endocrinology. 2020 Aug 1;161(8):bqaa101.
20 The somatostatin analog 188Re-P2045 inhibits the growth of AR42J pancreatic tumor xenografts. J Nucl Med. 2014 Dec;55(12):2020-5.
21 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
22 Role of somatostatin in the augmentation of hippocampal long-term potentiation by FR121196, a putative cognitive enhancer. Eur J Pharmacol. 1993 Sep 7;241(1):27-34.
23 Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
24 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
25 Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
26 17-Estradiol Activates HSF1 via MAPK Signaling in ER-Positive Breast Cancer Cells. Cancers (Basel). 2019 Oct 11;11(10):1533. doi: 10.3390/cancers11101533.
27 Ethyl carbamate induces cell death through its effects on multiple metabolic pathways. Chem Biol Interact. 2017 Nov 1;277:21-32.
28 Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
29 Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.
30 Chronic ethanol exposure increases goosecoid (GSC) expression in human embryonic carcinoma cell differentiation. J Appl Toxicol. 2014 Jan;34(1):66-75.
31 Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
32 Effects of progesterone treatment on expression of genes involved in uterine quiescence. Reprod Sci. 2011 Aug;18(8):781-97.
33 Discovery of (+)-N-(3-aminopropyl)-N-[1-(5-benzyl-3-methyl-4-oxo-[1,2]thiazolo[5,4-d]pyrimidin-6-yl)-2-methylpropyl]-4-methylbenzamide (AZD4877), a kinesin spindle protein inhibitor and potential anticancer agent. J Med Chem. 2011 Oct 13;54(19):6734-50. doi: 10.1021/jm200629m. Epub 2011 Sep 7.
34 CCAT1 is an enhancer-templated RNA that predicts BET sensitivity in colorectal cancer. J Clin Invest. 2016 Feb;126(2):639-52.
35 From transient transcriptome responses to disturbed neurodevelopment: role of histone acetylation and methylation as epigenetic switch between reversible and irreversible drug effects. Arch Toxicol. 2014 Jul;88(7):1451-68.
36 Transcriptome and DNA methylome dynamics during triclosan-induced cardiomyocyte differentiation toxicity. Stem Cells Int. 2018 Oct 29;2018:8608327.
37 DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
38 Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
39 Identification of transcriptome signatures and biomarkers specific for potential developmental toxicants inhibiting human neural crest cell migration. Arch Toxicol. 2016 Jan;90(1):159-80.
40 Effects of lithium and valproic acid on gene expression and phenotypic markers in an NT2 neurosphere model of neural development. PLoS One. 2013;8(3):e58822.
41 Exposure to Insecticides Modifies Gene Expression and DNA Methylation in Hematopoietic Tissues In Vitro. Int J Mol Sci. 2023 Mar 26;24(7):6259. doi: 10.3390/ijms24076259.
42 A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
43 Locoregional regulatory peptide receptor targeting with the diffusible somatostatin analogue 90Y-labeled DOTA0-D-Phe1-Tyr3-octreotide (DOTATOC): a pilot study in human gliomas. Clin Cancer Res. 1999 May;5(5):1025-33.
44 Preoperative growth inhibition of human gastric adenocarcinoma treated with a combination of celecoxib and octreotide. Acta Pharmacol Sin. 2007 Nov;28(11):1842-50. doi: 10.1111/j.1745-7254.2007.00652.x.
45 Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.